Aktie
WKN DE: A2DU6V / ISIN: US1897631057
14.08.2025 22:19:49
|
Co-Diagnostics Sales Plunge 93 Percent
Co-Diagnostics (NASDAQ:CODX), a diagnostics technology company focused on infectious disease testing, announced its Q2 2025 results on August 14, 2025. GAAP EPS loss of $0.23 was better than analysts' estimate of a $0.25 loss. However, GAAP revenue fell short at $0.2 million, compared to the $0.3 million analysts anticipated, and marking a sharp drop from $2.7 million in Q2 2024. While the loss shrank, revenue relied heavily on grant timing, accentuating the company’s ongoing pre-commercial phase. The quarter reflected both progress in product development and the financial pressures of a business not yet generating steady sales. Source: Analyst estimates for the quarter provided by FactSet. Co-Diagnostics specializes in molecular diagnostics, with a focus on infectious disease detection using polymerase chain reaction (PCR) technology. At its core is the proprietary Co-Primers technology, which is designed to enhance the accuracy and specificity of PCR tests by reducing common errors like false positives caused by primer-dimers. Its business centers on developing tests and platforms that can be used both at point-of-care settings and at home, aiming to offer affordable, accurate diagnostic solutions globally.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Co-Diagnostics Inc Registered Shsmehr Nachrichten
13.08.25 |
Ausblick: Co-Diagnostics stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) | |
07.05.25 |
Ausblick: Co-Diagnostics gewährt Anlegern Blick in die Bücher (finanzen.net) |
Analysen zu Co-Diagnostics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Co-Diagnostics Inc Registered Shs | 0,32 | 4,64% |
|